PMID- 22623877
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 5
DP  - 2012
TI  - Targeting bladder tumor cells in voided urine of Chinese patients with 
      FITC-CSNRDARRC peptide ligand.
PG  - 85-90
LID - 10.2147/OTT.S31368 [doi]
AB  - OBJECTIVE: To study the practicality of the FITC-CSNRDARRC peptide ligand 
      (containing the Cys-Ser-Asn-Arg-Asp-Ala-Arg-Arg-Cys nonapeptide) in diagnosing 
      and monitoring bladder tumors. MATERIALS AND METHODS: Between March 2011 and 
      September 2011, 80 consecutive patients with radiographic abnormalities, 
      localizing hematuria, other symptoms, or signs were studied using the 
      FITC-CSNRDARRC ligand, urinary cytology (UC), and fluorescence in situ 
      hybridization (FISH). The sensitivity and specificity of these three technologies 
      were determined and compared. Cystoscopy and tissue biopsy were taken as the 
      "gold standards" for bladder tumor diagnosis in this study. RESULTS: Twenty-nine 
      out of 80 patients were diagnosed with a bladder tumor via histopathological 
      examination. The FITC-CSNRDARRC ligand was positive in 23 out of 29 bladder tumor 
      patients and produced false negatives in six (20.69%) patients. The UC was 
      positive in six out of 29 bladder tumor patients and produced false negatives in 
      23 (79.31%) patients. The FISH was positive in 21 out of 29 bladder tumor 
      patients and produced false negatives in eight (27.59%) patients. The overall 
      sensitivity as verified by the FITC-CSNRDARRC ligand was much higher than in UC 
      (79.31% versus 20.69%, P < 0.001) and was slightly higher than in FISH (79.31% 
      versus 72.41%, P = 0.625). The sensitivity of FISH was significantly higher than 
      that of UC (72.41% versus 20.69%, P < 0.001). Sensitivities of the FITC-CSNRDARRC 
      ligand and UC by grade were 58.33% versus 8.3% for low-grade (LG) tumors (P = 
      0.031) and 94.12% versus 29.41% for high-grade (HG) tumors (P = 0.003), 
      respectively. The advantage was maintained in terms of the detection of invasive 
      tumors between the FITC-CSNRDARRC ligand and UC (90.48% versus 23.81%, P = 0.001) 
      as well as between FISH and UC (85.71% versus 23.81%, P = 0.003). The 
      specificities for the FITC-CSNRDARRC ligand, UC, and FISH were 100%. CONCLUSION: 
      Results show that the FITC-CSNRDARRC ligand is a promising noninvasive tool for 
      diagnosis and surveillance in patients suspected of having a new bladder tumor.
FAU - Jia, Xing-You
AU  - Jia XY
AD  - School of the First Clinical Hospital, Shanxi Medical University, Taiyuan, 
      Shanxi, China.
FAU - Yu, Qi
AU  - Yu Q
FAU - Zhang, Zhe-Hui
AU  - Zhang ZH
FAU - Yang, Xiao-Feng
AU  - Yang XF
LA  - eng
PT  - Journal Article
DEP - 20120507
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC3358809
OTO - NOTNLM
OT  - FITC-CSNRDARRC ligand
OT  - bladder tumor
OT  - fluorescent probe
OT  - tumor-targeting
EDAT- 2012/05/25 06:00
MHDA- 2012/05/25 06:01
PMCR- 2012/05/07
CRDT- 2012/05/25 06:00
PHST- 2012/05/25 06:00 [entrez]
PHST- 2012/05/25 06:00 [pubmed]
PHST- 2012/05/25 06:01 [medline]
PHST- 2012/05/07 00:00 [pmc-release]
AID - ott-5-085 [pii]
AID - 10.2147/OTT.S31368 [doi]
PST - ppublish
SO  - Onco Targets Ther. 2012;5:85-90. doi: 10.2147/OTT.S31368. Epub 2012 May 7.